## 1 **SLC25A26-mediated SAM compartmentalization coordinates translation and**  2 **bioenergetics during cardiac hypertrophy**  3 Ningning Guo<sup>1,2,3,4</sup>, Jian Lv<sup>1,2,3,4</sup>, Yu Fang<sup>1,2</sup>, Qiuxiao Guo<sup>1,2</sup>, Jiajie Li<sup>1</sup>, Junmei Wang<sup>1</sup>, Xiao 4 Ma<sup>2</sup>, Qingqing Yan<sup>2</sup>, Fuqing Jiang<sup>1,2</sup>, Shuiyun Wang<sup>1,2</sup>, Li Wang<sup>1,2,\*</sup>, Zhihua Wang<sup>1,2,\*</sup> 5 <sup>1</sup> 6 Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of 7 Medical Sciences, Shenzhen, Shenzhen 518057, China <sup>2</sup> 8 <sup>2</sup> State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for 9 Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical 10 College, Beijing 100037, China <sup>3</sup> Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, 12 China <sup>4</sup>These authors contribute equally 14 15 \*Correspondence to Zhihua Wang, PhD, Shenzhen Key Laboratory of Cardiovascular Disease, 16 Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen 518057, China. 17 Email: wangzhihua@fuwaihospital.org; or Li Wang, PhD, Shenzhen Key Laboratory of 18 Cardiovascular Disease, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, 19 Shenzhen 518057, China. Email: wangl@pumc.edu.cn. 20 21 **Running Title**: SAM links cardiac bioenergetics to translation 22 23 24

#### 25 **ABSTRACT**

26 **BACKGROUND**: The heart undergoes hypertrophy as a compensatory mechanism to cope with 27 increased hemodynamic stress, and it can transition into a primary driver of heart failure. 28 Pathological cardiac hypertrophy is characterized by excess protein synthesis. Protein translation 29 is an energy-intensive process that necessitates an inherent mechanism to flexibly fine-tune 30 intracellular bioenergetics according to the translation status; however, such a molecular link 31 remains lacking.

32 **METHODS**: *Slc25a26* knockout and cardiac-specific conditional knockout mouse models were 33 generated to explore its function *in vivo*. Reconstructed adeno-associated virus was used to 34 overexpress *Slc25a26 in vivo*. Cardiac hypertrophy was established by transaortic constriction 35 (TAC) surgery. Neonatal rat ventricular myocytes were isolated and cultured to evaluate the role 36 of SLC25A26 in cardiomyocyte growth and mitochondrial biology *in vitro*. RNA sequencing was conducted to explore the regulatory mechanism by SLC25A26.  $m<sup>1</sup>A$ -modified tRNAs were 38 profiled by RNA immuno-precipitation sequencing. Label-free proteomics was performed to 39 profile the nascent peptides affected by S-adenosylmethionine (SAM).

40 **RESULTS**: We show that cardiomyocytes are among the top cell types expressing the SAM 41 transporter SLC25A26, which maintains low-level cytoplasmic SAM in the heart. SAM 42 biosynthesis is activated during cardiac hypertrophy, and feedforwardly mobilizes the 43 mitochondrial translocation of SLC25A26 to shuttle excessive SAM into mitochondria. Systemic 44 deletion of *Slc25a26* causes embryonic lethality. Cardiac-specific deletion of *Slc25a26* causes 45 spontaneous heart failure and exacerbates cardiac hypertrophy induced by transaortic 46 constriction. SLC25A26 overexpression, both before or after TAC surgery, rescues the 47 hypertrophic pathologies and protects from heart failure. Mechanistically, SLC25A26 maintains



#### 59 **Clinical Perspective**

#### 60 **What Is New?**

- <sup>61</sup> An activation of S-adenosylmethionine (SAM) biosynthesis during cardiac hypertrophy 62 boosts a feed-forward mitochondrial translocation of its transporter SLC25A26 to shuttle 63 excessive SAM into mitochondria.
- <sup>64</sup> SLC25A26-mediated cytoplasmic SAM containment restricts translation through inhibiting 65 TRMT61A-mediated tRNA  $m<sup>1</sup>A$  modifications, particularly at A58 and A75, which 66 modulates translation initiation and codon usage.
- <sup>67</sup> SLC25A26-mediated mitochondrial SAM accumulation enhances mtDNA methylation and 68 is required for the implement of mitochondrial fission and mitophagy, therefore maintaining 69 optimal bioenergetics.
- <sup>70</sup> Cardiac-specific knockout of *Slc25a26* causes spontaneous heart failure, and exacerbates 71 transaortic constriction (TAC)-induced cardiac hypertrophy, while its overexpression 72 rescues the hypertrophic pathologies.
- 

#### 73 **What Are the Clinical Implications?**

- <sup>74</sup> Cardiomyocyte-specific expression of SLC25A26 maintains low-level cytoplasmic SAM 75 and contributes to the relatively low protein synthesis rate in the heart.
- <sup>76</sup> Targeting intracellular SAM distribution would be a promising therapeutic strategy to treat 77 cardiac hypertrophy and heart failure.

## 79 **Nonstandard Abbreviations and Acronyms**





80

### 82 **INTRODUCTION**

83 Cardiomyocytes predominantly express myofilament-related proteins, which constitute more than half of the entire translatome.<sup>1</sup> The contraction and relaxation of the myofilament require substantial energy to maintain optimal cardiac performance.<sup>2, 3</sup> Notably, translation also 86 consumes a significant portion of the cellular energy expenditure *per se*.<sup>4-6</sup> The translation activity is stringently monitored to ensure appropriate justification of the energetic investment.<sup>6</sup> 88 Thus, the interplay between contractility, translation and bioenergetics forms a complex triadic 89 entanglement in working cardiomyocytes. In theory, there should be an inherent mechanism that 90 coordinates these processes to provide cardiomyocytes with the necessary adaptability under 91 pathophysiological conditions; however, such a molecular link is still lacking.<sup>7, 8</sup>

92 The heart undergoes hypertrophy as a compensatory mechanism to cope with increased 93 hemodynamic stress; however, if the stress persists without timely relief, hypertrophy can transition into a primary driver of heart failure.<sup>9</sup> Pathological cardiac hypertrophy is 95 characterized by enlarged cardiomyocyte size and excess protein synthesis.<sup>10-12</sup> Despite early  $\frac{13-15}{100}$  indications of increased ribosome biogenesis,  $\frac{13-15}{100}$  little headway has been made in understanding the regulatory mechanisms governing translational control during cardiac hypertrophy.<sup>16</sup> While 98 gene abnormalities in cardiac hypertrophy have been extensively examined at the transcriptional 99 level, it is important to note that the cardiac translatome cannot be precisely dictated by the 100 transcriptome due to ribosome efficacy and mRNA selectivity.<sup>17-20</sup>

101 The pathological growth of cardiomyocytes is accompanied by an enhancement of translation initiation.<sup>12</sup> Phosphorylation of eukaryotic translation initiation factor 2Bε by 103 glycogen synthase kinase-3β contributes to the enhanced translation activity in β-adrenergic 104 cardiac hypertrophy.<sup>21</sup> A recent study revealed that activation of inositol-requiring enzyme  $1\alpha$ 

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.07.30.24311193;](https://doi.org/10.1101/2024.07.30.24311193) this version posted August 2, 2024. The copyright holder for this preprint



114 Regulations at the tRNA level play a crucial role in fine-tuning protein synthesis in response to various cellular conditions and signals.<sup>28</sup> Modifications to tRNAs affect their 116 stability, aminoacylation, and codon recognition properties, ultimately influencing the overall translation process.<sup>29</sup> The initiator tRNA (tRNA<sup>iMet</sup>) can be methylated at the N(1) position of 118  $A58$  (m<sup>1</sup>A58) by the tRNA methyltransferase (TRMT)  $6/61A$  complex, leading to an enhancement of translation initiation.<sup>30, 31</sup> Moreover, tRNA modifications can change the status 120 of the tRNA pool, leading to biased codon usage and altered translating rate of individual  $121$  mRNAs.<sup>32</sup> However, it remain unclear whether tRNA modifications are involved in the 122 translational control during cardiac hypertrophy.

123 The energetic cost of protein synthesis accounts for ~30% of the total energy consumption in mammalian cells.<sup>5</sup> In the heart, up to 95% of adenosine triphosphate (ATP) is 125 derived from mitochondria, which occupy  $\approx 30\%$  of the total myocardial mass.<sup>33</sup> Mitochondrial 126 fitness is crucial for maintaining the normal heart function; and its disorder plays a causal role in heart diseases.<sup>34-36</sup> Mitochondrial oxidative capacity has been reported to be either preserved or

128 even enhanced in cardiac hypertrophy,<sup>37</sup> but the regulatory mechanism of mitochondrial 129 dynamics under hypertrophic stress remains to be elucidated.

130 S-adenosylmethionine (SAM) is the sole methyl donor for macromolecular methylation reactions.<sup>38</sup> Its biosynthesis is catalyzed by methionine adenosyltransferase 2A (MAT2A) using 132 methionine and ATP as the substrates.<sup>39</sup> The mitochondrial shuttling of SAM requires a transporter named solute carrier family 25 member 26 (SLC25A26; also known as SAMC).<sup>40</sup> We 134 find that the cardiomyocytes express low-level MAT2A but high-level SLC25A26, making 135 mitochondria a pool of the intracellular SAM. Whereas the cytoplasmic SAM (cytoSAM) 136 enhances translation activity via tRNA  $m<sup>1</sup>A$  modification, the mitochondrial SAM (mitoSAM) 137 maintains mitochondrial fitness through promoting fission and mitophagy. During cardiac 138 hypertrophy, an increase in SAM biosynthesis boosts the mitochondrial translocation of 139 SLC25A26 in a feedforward manner to transport excessive cytoSAM into mitochondria. 140 Cardiac-specific deletion of *Slc25a26* in mice causes spontaneous heart failure and exacerbates 141 cardiac hypertrophy induced by transaortic constriction, whereas its overexpression rescues the 142 hypertrophic pathologies. Our findings demonstrate that subcellular distribution of SAM links 143 bioenergetics with translation in cardiomyocytes, and represents a promising target for the 144 treatment of cardiac hypertrophy and heart failure.

145

## 146 **METHODS**

147 Collection and usage of human samples were approved by the Ethics Committee of the Fuwai 148 Hospital Chinese Academy of Medical Sciences, Shenzhen [SP2023133(01)]. Animal 149 experiments were reviewed and approved by the Institutional Animal Care and Use Committee 150 (IACUC) of Renmin Hospital of Wuhan University (No. 20180508) and the IACUC of Fuwai



#### 153 **Data Availability**

154 RNA-seq data have been deposited in NCBI's Gene Expression Omnibus (GEO) repository 155 (accession: GSE254565 and GSE173737). Online microarray datasets are available from NCBI's 156 GEO repository with corresponding accession codes as described in details in Supplemental 157 Methods. Any additional information reported in this paper is available from the lead contact 158 upon request.

#### 159 **Statistical Analyses**

160 Statistical analyses were performed using GraphPad Prism 8.0 and R software. All experimental 161 data were presented as mean  $\pm$  SEM of at least three independent experiments, unless denoted 162 elsewhere. Statistical significance for multiple comparisons was determined by one-way 163 ANOVA or two-way ANOVA followed by Tukey's test. Bonferroni adjustment was used for 164 *post hoc* analysis. Student's *t* test was used for comparisons between two groups. *P* < 0.05 was 165 considered statistically significant.

166

#### 167 **RESULTS**

#### 168 **Feedforward Mitochondrial SAM Transport by SLC25A26 during Cardiac Hypertrophy**

SAM is mainly synthesized by MAT2A in cytosol,<sup>41</sup> and can be shuttled into mitochondria by 170 SLC25A26 before donating its methyl group (Figure 1A). Human single-cell sequencing data 171 highlighted skeletal myocytes as the cell type with the highest *MAT2A* expression, versus 172 cardiomyocytes to be the lowest one (Figure 1B). On the contrary, cardiomyocytes were among



182 We then asked how the SAM biology would be shaped under cardiac stress. Both 183 MAT2A and its regulatory subunit MAT2B were significantly upregulated during the 184 development of cardiac hypertrophy after transaortic constriction (TAC) surgery in mice (Figure 185 1F), concurrent with a time-course increase in the SAM content (Figure 1G). In isolated neonatal 186 rat ventricular myocytes (NRVMs), hypertrophic stimulation by phenylephrine (PE; 50μM) also 187 increased the SAM content to a similar extent as exogenous SAM supplementation (1μM; Figure 188 1H). The PE-induced SAM increase was completely blocked by an MAT2A inhibitor AG-270 189 (3uM; Figure 1H), <sup>42</sup> suggesting an activation of SAM biosynthesis during cardiac hypertrophy.

190 Nevertheless, the expression of SLC25A26 showed a significant decrease after TAC 191 (Figure 1F), which was consistent with observations in human hearts with dilated 192 cardiomyopathy and mouse TAC databases (Figures S1C and S1D). Despite a decrease in 193 SLC25A26 expression, the level of mitoSAM was still significantly elevated by TAC (Figure 1I), 194 indicating an alteration of SAM-transporting activity. To our surprise, albeit originally designated as a mitochondrial protein,  $40$  significant amount of SLC25A26 was detected in the 196 cytoplasmic fraction of both human and mouse hearts (Figure 1J). Yet TAC surgery caused

197 substantial translocation of SLC25A26 from cytosol to mitochondria (Figure 1K). Consistently, 198 PE treatment in NRVMs also promoted the mitochondrial translocation of SLC25A26, an effect 199 that could be mimicked by supplementing SAM but blocked by AG-270 (Figure 1L). These data 200 suggest that the increased SAM biosynthesis during cardiac hypertrophy promotes the 201 mitochondrial translocation of SLC25A26, thereby shuttling excessive cytoSAM into 202 mitochondria in a feed-forward manner.

#### 203 **SLC25A26 Is Required for Development and Normal Heart Function**

204 To investigate the physiological function of SLC25A26, we tried to generate an *Slc25a26*- 205 knockout mouse line using CRISPR-cas9 (Figures S2A and S2B). However, homozygous 206 knockout of *Slc25a26* caused embryonic lethality (Figure S2C), suggesting an essential role of 207 SLC25A26 in development. This is consistent with previous observations that loss-of-function 208 mutations of human *SLC25A26* resulted in neonatal mortality.<sup>43-45</sup>

209 We then developed an inducible cardiac-specific conditional knockout (cKO) mouse line 210 by generating an *Slc25a26*-flox mouse line and hybridizing the mice with the αMHC-211 MerCreMer transgenic mice (Figure 2A), so that enabling controllable *Slc25a26* deletion in adult 212 cardiomyocytes (Figure 2B).<sup>46</sup> Slc25a26 cKO did not influence the heart weight but significantly 213 increased the lung weight twenty weeks after tamoxifen administration (Figures 2C and 2D), a 214 characteristic symptom of heart failure. Echocardiography showed that *Slc25a26* deficiency led 215 to enlarged left ventricular internal diameter (LVID) both in diastole and in systole and impaired 216 the ejection fraction (EF) and fraction shortening (FS) (Figures 2E through 2G). Moreover, the 217 *Slc25a26*-cKO hearts exhibited severe myocardial fibrosis (Figure 2H) and robust inductions of 218 pathological markers, including natriuretic peptide A (*Nppa*), natriuretic peptide B (*Nppb*), and 219 myosin heavy chain 7 (*Myh7*), compared with the *Slc25a26*-flox hearts (Figure 2I). These data

220 suggest an essential role of SLC25A26 in the maintenance of normal heart morphology and 221 function.

222 **SLC25A26 Suppresses Cardiac Hypertrophy** 

223 To evaluate the impact of SLC25A26 on pathological cardiac hypertrophy, we subjected the 224 *Slc25a26*-cKO mice (5w after tamoxifen administration) to TAC surgery. Loss of *Slc25a26* 225 significantly elevated the TAC-induced heart weight gain (Figure 2J), and caused severe 226 pulmonary edema in the TAC group (Figure 2K). Echocardiography detected an increased left 227 ventricular posterior wall (LVPW) thickness after TAC, without any change in LVID, in the 228 *Slc25a26*-cKO hearts compared with the *Slc25a26*-flox hearts (Figures 2L and 2M). Moreover, 229 deletion of *Slc25a26* exacerbated the TAC-induced contractility impairment and accelerated the 230 development of heart failure (Figure 2N). At the histological level, *Slc25a26* cKO aggravated the 231 TAC-induced cardiomyocyte enlargement (Figures 2O and 2P) and myocardial fibrosis (Figure 232 2Q). At the molecular level, the post-TAC inductions of *Nppa*, *Nppb*, and *Myh7* were further 233 potentiated by *Slc25a26* deficiency (Figure 2R). Consistently, *Slc25a26* haploinsufficiency also 234 exhibited worsened hypertrophic pathologies after TAC (Figures S2D through S2J). These data 235 highlight a protective role of SLC25A26 against cardiac hypertrophy.

236 To examine the inhibitory effect of SLC25A26 on cardiac hypertrophy, we reconstructed 237 adeno-associated virus (AAV9) to overexpress *Slc25a26* in the heart two weeks before TAC 238 surgery (Figures 3A and 3B). *Slc25a26* overexpression significantly restricted the TAC-induced 239 heart weight gain compared with the AAV9-*Vector* control group (Figure 3C). Echocardiography 240 showed that the post-TAC enlargements of LVPW thickness and LVID were significantly 241 blunted by *Slc25a26* overexpression (Figures 3D and 3E); and the post-TAC declines of EF and 242 FS were significantly rescued by *Slc25a26* overexpression (Figure 3F). Moreover, *Slc25a26*



255 In line with the *in vivo* findings, the PE-induced hypertrophy of NRVMs was 256 significantly exacerbated by silencing *Slc25a26*, but alleviated by its overexpression (Figures 257 S3A through S3F).

#### 258 **SLC25A26 Negatively Regulates Translation Activity**

259 To explore the underlying mechanisms, we performed a transcriptome analysis. Principal 260 component analysis showed that *Slc25a26* deficiency caused a generally pro-hypertrophic 261 transcriptome reprogramming (Figure 4A). Gene-concept network analysis highlighted the 262 pathways of aminoacyl-tRNA ligase activity and tRNA aminoacylation for protein translation 263 among the top enriched functional terms affected by *Slc25a26* deletion (Figure 4B). In detail, 264 nearly all cytosol aminoacyl-tRNA synthetases, but not their mitochondrial counterparts, were 265 substantially upregulated in the *Slc25a26*-cKO hearts compared with the *Slc25a26*-flox controls

266 (Figure 4C). Concurrently, gene set enrichment analysis revealed a remarkable upregulation of 267 ribosome-biogenesis-associated genes (Figure 4D), suggesting a crucial role of SLC25A26 in 268 translational regulation.

269 We then performed an *in vivo* puromycin incorporation assay to directly assess 270 translation activity. The heart presented the lowest protein synthesis rate among the organs tested 271 (Figure S4A). The protein synthesis rate was significantly accelerated in the *Slc25a26*-cKO 272 hearts but suppressed in the hearts with *Slc25a26* overexpression, compared with corresponding 273 controls (Figures 4E and 4F). Consistently, silencing *Slc25a26* in NRVMs significantly 274 accelerated the protein synthesis rate and further enhanced its activation by PE (Figure S4B), 275 while *Slc25a26* overexpression exhibited opposite effects (Figure S4C). However, *Slc25a26* 276 knockdown failed to re-activate translation when the SAM biosynthesis was inhibited by AG-277 270, which displayed robust suppression on basal translation activity (Figures S4D and S4E). On 278 the other hand, SAM supplementation largely rescued the inhibitory effect of *Slc25a26* 279 overexpression on translation (Figure S4F). These data suggest that the translation-repressing 280 role of SLC25A26 relies on its function as a SAM transporter.

#### 281 **SLC25A26 Modulates tRNA m<sup>1</sup>A Profiles and Translation Initiation**

282 Since SAM-dependent tRNA methylation is critical for its maturation and the decoding process 283 during translation,<sup>47, 48</sup> we hypothesized that SLC25A26-mediated cytoSAM containment might 284 regulate translation through modulating tRNA methylation. In the *Slc25a26*-cKO hearts, an 285 increase in cytoSAM did not affect the  $N(6)$ -methyladenosine  $(m<sup>6</sup>A)$  level of total RNAs, but 286 significantly enhanced the level of  $m<sup>1</sup>A$  (Figure 4G), a modification that mainly occurs on 287 tRNAs.<sup>47-49</sup> Then we performed RNA immunoprecipitation sequencing (RIP-seq) using an m<sup>1</sup>Aspecific antibody to profile the tRNA  $m<sup>1</sup>A$  landscape at single-nucleotide resolution. Out of the



#### 298 **SAM-sensitive tRNA m<sup>1</sup>A Patterns Remodel Cardiac Translatome**

299 Status of the tRNA pool determines codon usage that influences the translating rate of 300 individual mRNAs.<sup>32, 50</sup> We found that the m<sup>1</sup>A modifications after *Slc25a26* deletion were 301 diversified among different tRNA categories (Figure 4J), as well as among different tRNA 302 isotypes for certain amino acids (Figures 4K and 4L). For instance, the m<sup>1</sup>A levels were largely 303 elevated in corresponding tRNAs of Asn, Asp, Cys, Ser, Val and Sec (selenocysteine), but were 304 reduced in those for Ala, His, Trp and Sup (stop codon) after *Slc25a26* knockout (Figure 4J).

 $305$  To characterize the impact of the cytoSAM-sensitive tRNA  $m<sup>1</sup>A$  modifications on 306 translation dynamics, we performed a label-free proteomics analysis for the enriched puromycin-307 incorporated nascent peptides from NRVMs with different *Slc25a26* manipulations (Figure 4M). 308 We identified 4262 peptides corresponding to 713 proteins, among which 203 proteins were 309 altered by *Slc25a26* knockdown and 92 proteins were altered by its overexpression (Figure 4N). 310 Surprisingly, heart-specific proteins, such as myosin heavy chain (MYH) 6/7, myosin light chain 311 (MYL) 4/6, and Xin actin binding repeat containing (XIRP) 2, were enriched in the

312 downregulated proteins after *Slc25a26* knockdown (Figure 4O). Whereas proteins related to 313 ribosome and cardiac muscle contraction were suppressed by *Slc25a26* knockdown, proteasome-314 related proteins were highly enriched in the upregulated proteins (Figure 4P). Slc25a26 315 overexpression generally showed an opposite regulation of these pathways (Figure 4Q). These 316 data suggest a compensatory response to reduce ribosome biogenesis and to augment protein 317 degradation upon *Slc25a26* deficiency. When mapped to the transcriptional changes, roughly 318 61% proteins, such as XIRP1, MYL4, MYL6, guanylate binding protein 1, signal transducer and 319 activator of transcription 1, tripartite motif containing 21, and collagen type I alpha 1, showed 320 consistent alterations with their mRNA levels; whereas 39% proteins, such as XIRP2, 321 sequestosome 1 (SQSTM1), receptor for activated C kinase 1, and junction plakoglobin, could 322 not be interpreted by their transcriptional alterations (Figure 4R). These data suggest that 323 SLC25A26-mediated biased codon usage remodels cardiac translatome.

## **tRNA m1** <sup>324</sup>**A Modification Contributes to SLC25A26-mediated Translational Control**

325 When aligning all the  $m^1A$  sites together, we found that the SAM-sensitive  $m^1A$ 326 modification mainly occurred within the T-arm and the acceptor region of tRNAs, particularly at 327 A58 and A75 (the last nucleotide for esterification with cognate amino acids) (Figure 5A). 328 Typical m<sup>1</sup>A-modified sites were illustrated in tRNA<sup>IMet</sup>, tRNA<sup>Gln</sup>, and tRNA<sup>Thr</sup> (Figure 5B). However, two tRNA categories, tRNA<sup>Glu</sup> and tRNA<sup>Gly</sup>, exhibited distinct m<sup>1</sup>A modification 330 patterns specifically in the D arm (Figure 5C). The  $m<sup>1</sup>A75$  modification has not been reported  $b$  331 before, but the m<sup>1</sup>A58 modification is well-known for its critical role in tRNA maturation and coding.<sup>47-49</sup> TRMT6 and TRMT61A function as the methyltransferases for A58 of tRNAs;<sup>51-53</sup> 333 however, only TRMT61A could be verified necessary for maintaining the normal translation 334 activity in NRVMs (Figures 5D and 5E). Silencing *Trmt61a* significantly reversed the 335 acceleration of the protein synthesis rate by *Slc25a26* knockdown (Figure 5F). Moreover,



344 **mitoSAM Maintains Mitochondrial Fitness for Optimal Energy Production** 

SAM-dependent methylation reactions are crucial for the normal function of mitochondria.<sup>57</sup> so 346 we became curious about the impact of SLC25A26 on mitochondrial biology. The mitoSAM 347 level in the heart was reduced by *Slc25a26* cKO but increased by its overexpression (Figure 6A).  $348$  Nuclear DNA represents a primary methylation substrate sensitive to SAM abundance;  $43$ 349 however, it remains under debate whether the mitochondrial DNA (mtDNA) can be 350 methylated.<sup>58</sup> To address this question, we performed mass spectrometry with purified mtDNA, 351 and found that SLC25A26-mediated mitoSAM accumulation significantly increased the level of 352 5-methyl-2'-deoxycytidine (5-mdC) with marginal effects on 5-(hydroxymethyl)-2'- 353 deoxycytidine (5-hmdC) or N6-methyl-2'-deoxyadenosine (6-mdA) in mtDNA (Figure 6B). 354 ELISA analysis also confirmed that the 5-mdC amount of mtDNA was reduced in the *Slc25a26*- 355 cKO hearts but augmented in the hearts with *Slc25a26* overexpression, compared with 356 corresponding controls (Figure 6C). Moreover, *Slc25a26* overexpression in NRVMs increased 357 the 5-mdC level in mtDNA but reduced that in the nuclear DNA (Figure S6A). Nevertheless, 358 *Slc25a26* manipulations did not influence the mitochondria copy number (Figures 6D and S6B).

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.07.30.24311193;](https://doi.org/10.1101/2024.07.30.24311193) this version posted August 2, 2024. The copyright holder for this preprint

359 Transmission electron microscope showed that *Slc25a26* deficiency significantly 360 impaired the mitochondrial morphology in the heart (Figure 6E), whereas *Slc25a26* 361 overexpression significantly ameliorated the severity of mitochondrial damage after TAC (Figure 362 6F). To explore the underlying mechanism, we screened the expression of proteins related to 363 mitochondrial dynamics. Whereas the fusion-related proteins mitofusin 2 (MFN2) and 364 mitochondrial dynamin-like GTPase (OPA1) did not change after *Slc25a26* deletion, the fission-365 related proteins dynamin-related protein 1 (DRP1) and mitochondrial fission factor (MFF) were 366 significantly down-regulated (Figure 6G). Moreover, *Slc25a26* deficiency caused significant 367 accumulation of mitophagy-related proteins Parkin and SQSTM1 (also known as p62), but 368 inhibited microtubule associated protein 1 light chain 3 (LC3) lipidation (Figure 6G), suggesting 369 a stagnancy of mitophagy. Similar alteration patterns were observed in NRVMs with *Slc25a26* 370 knockdown (Figure S6C). Furthermore, inhibiting SAM biosynthesis by AG-270 caused a 371 significant decrease of MFF and accumulation of SQSTM1 in despite of a complete depletion of  $Parkin$  (Figure S6D). Fluorescent imaging with mito-Keima, a mitophagy indicator,  $59$  showed 373 that *Slc25a26* knockdown in NRVMs significantly reduced the engulfment of mitochondria by 374 lysosome (Figure 6H), and this process was oppositely promoted by *Slc25a26* overexpression 375 (Figure 6I). These data suggest that the mitochondrial uptake of SAM is required for the 376 implementation of mitochondrial fission and mitophagy, which are sequentially dependent  $\frac{377}{200}$  processes for mitochondrial quality control.<sup>60</sup>

378 To validate the functional outcome, we performed the JC-1 staining to measure the 379 mitochondrial membrane potential. PE-induced decline in mitochondrial membrane potential 380 was significantly exacerbated by *Slc25a26* knockdown (Figure 6J), but reversed by its 381 overexpression (Figure 6K). Consistently, mitochondrial bioenergetics assay (Seahorse) showed 382 that *Slc25a26* knockdown substantially impaired the mitochondrial respiratory capacity (Figure

383 6L), whereas its overexpression caused an improvement in oxygen consumption rate and ATP 384 production in an AG-270-sensitive manner (Figure 6M). These results suggest that SLC25A26- 385 mediated mitochondrial fitness benefits cardiac bioenergetics, thereby synchronizing the energy 386 production efficacy with the translation status.

387

#### 388 **DISCUSSION**

389 Coordination between translation and bioenergetics is prerequisite for cell flexibility in varying environments; however, such a molecular link is still missing.<sup>4-6, 8</sup> Our study demonstrates an 391 essential role of SLC25A26-mediated SAM compartmentalization in coordinating translational 392 control and mitochondrial quality control in cardiomyocytes, thus providing the first proof to 393 address this long-standing question.

394 As the principal methyl donor, the fundamental role of SAM in life activities is self-395 evident. Firstly, the methyl group is the simplest organic structural unit. Secondly, SAM is 396 derived from methionine, the start amino acid for translation initiation. Thirdly, SAM 397 metabolism pathways are highly conserved among organisms.<sup>61</sup> Nonetheless, our current 398 understanding about the regulation of SAM biology under pathophysiological conditions remains 399 limited. Here we reveal an increased SAM biosynthesis during the development of cardiac 400 hypertrophy, which drives the mitochondrial translocation of SLC25A26 to shuttle excessive 401 cytoSAM into mitochondria. This regulatory circuit manifests a rare feedforward mechanism that 402 provides a reasonable explanation for the relatively low-level cytoSAM compared to mitoSAM 403 in the heart. It is astonishing that endogenous SLC25A26 is not strictly a mitochondrial protein 404 as originally proposed in Chinese hamster ovary  $(CHO)$  cells<sup>40</sup>. In cardiomyocytes, the 405 mitochondrial location of SLC25A26 is adjustable depending on the cellular SAM abundance

406 (Figures 1K and 1L). This is supported by a previous report by Wang et al.<sup>62</sup> that SLC25A26 was 407 partially co-localized with mitochondria and could form hexamer, a possible existence form in 408 cytosol, as analyzed by size-exclusion chromatography.

409 The fact that the expression of SLC25A26 is mostly enriched in the heart indicates a 410 special need of the cardiomyocyte to balance the levels of cytoSAM and mitoSAM. In fact, the 411 protein synthesis rate in the heart is among the slowest compared with other tissues (Figure 412 S4A). This concept is further supported by previous observations that the turnover of cardiac 413 sarcomere proteins was relatively slow to maintain normal contractile function<sup>10, 20, 63</sup>. Our data 414 showed that the protein synthesis rate was highly sensitive to the expression alteration of 415 SLC25A26 (Figures 4E, 4F, and S4B-S4F), suggesting that the strict translational control in 416 cardiomyocytes might be attributable to the low-level cytoSAM maintained by SLC25A26.

All 417 Cur findings verify tRNA  $m<sup>1</sup>A$  modification to be the key mechanism underpinning the 418 translational control by SLC25A26 and cytoSAM. The  $m<sup>1</sup> A58$  modification is a conserved 419 feature of all tRNA variants, and has been thought to aid tRNA maturation, stability and 420 decoding.<sup>47-49</sup> Evidence in this study implicates that  $m<sup>1</sup> A58$  is not strictly required for the 421 housekeeping function of the tRNA but can be regulated by SAM availability, and serves as a 422 gearbox to finetune the translation efficiency. The  $m<sup>1</sup> A58$  modification on tRNA<sup>iMet</sup> has been 423 reported to promote translation initiation, but its pathophysiological relevance in human diseases has been lacking until very recently.<sup>54</sup> The alteration in  $m<sup>1</sup> A58$  level provides a mechanistic 425 explanation for how proteins are excessively synthesized during cardiac hypertrophy as a result 426 of enhanced SAM biosynthesis. Our data also validated the bidirectional regulation of  $m<sup>1</sup> A58$  by 427 the writer TRMT61A and the erasers  $ALKBH1/3$ <sup>52-54</sup> These modulators provide a 428 comprehensive tool box to modify the translation status by manipulating the level of  $m<sup>1</sup> A58$ . Moreover, we identified  $m<sup>1</sup>A75$  for the first time as a novel methylation event that was

430 remarkably abundant in tRNAs (Figure 5A). Considering that this is the last nucleotide for esterification with cognate amino acids,  $m<sup>1</sup>A75$  might have crucial functions in translational 432 regulation.

433 Beyond translation initiation, we also provide proof-of-concept evidence for the biased 434 codon usage derived from diversified tRNA  $m<sup>1</sup>A$  modifications in mammalian cells. The uneven 435 use of synonymous codons in the transcriptome serves as a secondary genetic code guiding 436 translation efficiency and fidelity.<sup>64</sup> Synonymous codon usage can have a substantial influence <sup>437</sup> on protein synthesis rates.<sup>65</sup> Highly expressed genes exhibit improved adaptation of the codons to 438 the tRNA pool.<sup>66</sup> Li et al.<sup>67</sup> found that tRNA m<sup>5</sup>C modification stabilizes tRNA<sup>Leu</sup>, contributing 439 to a codon-dependent translation bias to support a pro-cancer translation program. Our data quaranteerive term and that m<sup>1</sup>A modifications to different tRNA variants and different isotypes of certain tRNA 441 category possess diversified sensitivity to the SAM availability. This mechanism is preferentially 442 leveraged by the cardiomyocytes to tailor the proteome under hypertrophic stress. Nevertheless, 443 how these changes participate in pathogenesis of cardiac hypertrophy requires further validation 444 in details.

445 Mitochondrial fission enables clearance of dysfunctional mitochondria through 446 mitophagy to maintain the integrity of the energy system.<sup>60</sup> The high enrichment of SAM makes 447 mitochondria a pool for intracellular SAM, a unique pattern usually adopted by ions (e.g. 448 calcium) rather than metabolites. SLC25A26-mediated increase in mitoSAM is accompanied by 449 enhanced mitochondrial fission, mitophagy and ATP production, suggesting an important role of 450 SLC25A26/mitoSAM in mitochondrial quality control. Although we did not clarify the direct 451 effectors, the regulation of mitochondrial biology by mitoSAM is closely related to its impact on 452 mtDNA methylation. Certain isoforms of DNA methyltransferases can enter mitochondria to 453 catalyze mtDNA methylation, which has been associated with mitochondrial replication,

454 dynamics and bioenergetics.<sup>68, 69</sup>  $Slc25a26$  mutations in human cause intra-mitochondrial 455 methylation deficiency, and are associated with neonatal mortality resulting from respiratory 456 insufficiency and hydrops, childhood acute episodes of cardiopulmonary failure, and slowly 457 progressive muscle weakness,  $43-45$  suggesting an essential role of SLC25A26-mediated 458 mitochondrial homeostasis during development.

459 Putting the differential functions of cytoSAM and mitoSAM in the context of cardiac 460 hypertrophy, a rational deduction is that the enhanced SAM biosynthesis and transport are 461 intrinsic protective mechanisms to compensate for the increased contractility and energy 462 demands of cardiomyocytes under pressure overload. However, excessive protein synthesis 463 under long-term stress might exhaust the mitochondria for faster and faster ATP generation, 464 eventually leading to decompensation and the transition from cardiac hypertrophy to heart 465 **In this case, SLC25A26** overexpression is efficient to lower cytoSAM but increase 466 mitoSAM, resulting in translation slowdown and mitochondrial fitness. This scenario provides a 467 promising gene-therapy strategy to kill two birds with one stone.

468 Taken together, our study demonstrates SLC25A26-mediated SAM compartmentalization 469 as a molecular link between translation control and mitochondrial quality control. Targeting 470 intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac 471 hypertrophy and heart failure.

472

#### 473 **ARTICLE INFORMATION**

#### 474 **Affiliations**

475 Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Shenzhen Hospital Chinese 476 Academy of Medical Sciences (NG, JLv, YF, QG, JLi, JW, FJ, SW, LW, ZW), State Key





500 Supplemental References

501

#### 502 **REFERENCES**



- 506 2. Ventura-Clapier R, Garnier A, Veksler V and Joubert F. Bioenergetics of the failing heart.
- 507 *Biochim Biophys Acta*. 2011;1813:1360-72.
- 508 3. Muangkram Y, Noma A and Amano A. A new myofilament contraction model with ATP 509 consumption for ventricular cell model. *J Physiol Sci*. 2018;68:541-554.
- 510 4. Buttgereit F and Brand MD. A hierarchy of ATP-consuming processes in mammalian 511 cells. *Biochem J*. 1995;312 ( Pt 1):163-7.
- 512 5. Li GW, Burkhardt D, Gross C and Weissman JS. Quantifying absolute protein synthesis 513 rates reveals principles underlying allocation of cellular resources. *Cell*. 2014;157:624-35.
- 514 6. Marchingo JM and Cantrell DA. Protein synthesis, degradation, and energy metabolism 515 in T cell immunity. *Cell Mol Immunol*. 2022;19:303-315.
- 516 7. Kamoun D, Behar J, Leichner JM and Yaniv Y. Bioenergetic Feedback between Heart 517 Cell Contractile Machinery and Mitochondrial 3D Deformations. *Biophys J*. 2018;115:1603- 518 1613.
- 519 8. Yang X, Heinemann M, Howard J, Huber G, Iyer-Biswas S, Le Treut G, Lynch M, 520 Montooth KL, Needleman DJ, Pigolotti S, Rodenfels J, Ronceray P, Shankar S, Tavassoly I, 521 Thutupalli S, Titov DV, Wang J and Foster PJ. Physical bioenergetics: Energy fluxes, budgets,

522 and constraints in cells. *Proc Natl Acad Sci U S A*. 2021;118.

- 523 9. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ,
- 524 Maron MS and Sherrid MV. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC

525 State-of-the-Art Review. *J Am Coll Cardiol*. 2022;79:372-389.

- 526 10. Lam MP, Wang D, Lau E, Liem DA, Kim AK, Ng DC, Liang X, Bleakley BJ, Liu C,
- 527 Tabaraki JD, Cadeiras M, Wang Y, Deng MC and Ping P. Protein kinetic signatures of the 528 remodeling heart following isoproterenol stimulation. *J Clin Invest*. 2014;124:1734-44.
- 529 11. Maillet M, van Berlo JH and Molkentin JD. Molecular basis of physiological heart 530 growth: fundamental concepts and new players. *Nat Rev Mol Cell Biol*. 2013;14:38-48.
- 531 12. Nakamura M and Sadoshima J. Mechanisms of physiological and pathological cardiac 532 hypertrophy. *Nat Rev Cardiol*. 2018;15:387-407.
- 533 13. Morgan HE, Siehl D, Chua BH and Lautensack-Belser N. Faster protein and ribosome 534 synthesis in hypertrophying heart. *Basic Res Cardiol*. 1985;80 Suppl 2:115-8.
- 535 14. Rosello-Lleti E, Rivera M, Cortes R, Azorin I, Sirera R, Martinez-Dolz L, Hove L, Cinca 536 J, Lago F, Gonzalez-Juanatey JR, Salvador A and Portoles M. Influence of heart failure on
- 537 nucleolar organization and protein expression in human hearts. *Biochem Biophys Res Commun*. 538 2012;418:222-8.
- 539 15. Guo N, Zheng D, Sun J, Lv J, Wang S, Fang Y, Zhao Z, Zeng S, Guo Q, Tong J and Wang
- 540 Z. NAP1L5 Promotes Nucleolar Hypertrophy and Is Required for Translation Activation During 541 Cardiomyocyte Hypertrophy. *Front Cardiovasc Med*. 2021;8:791501.
- 542 16. Hannan RD, Jenkins A, Jenkins AK and Brandenburger Y. Cardiac hypertrophy: a matter
- 543 of translation. *Clin Exp Pharmacol Physiol*. 2003;30:517-27.
- 544 17. Witte F, Ruiz-Orera J, Mattioli CC, Blachut S, Adami E, Schulz JF, Schneider-Lunitz V, 545 Hummel O, Patone G, Mucke MB, Silhavy J, Heinig M, Bottolo L, Sanchis D, Vingron M,





- 594 29. Gu C, Begley TJ and Dedon PC. tRNA modifications regulate translation during cellular 595 stress. *FEBS Lett*. 2014;588:4287-96.
- 596 30. Macari F, El-Houfi Y, Boldina G, Xu H, Khoury-Hanna S, Ollier J, Yazdani L, Zheng G, 597 Bieche I, Legrand N, Paulet D, Durrieu S, Bystrom A, Delbecq S, Lapeyre B, Bauchet L, 598 Pannequin J, Hollande F, Pan T, Teichmann M, Vagner S, David A, Choquet A and Joubert D. 599 TRM6/61 connects PKCalpha with translational control through tRNAi(Met) stabilization: 600 impact on tumorigenesis. *Oncogene*. 2016;35:1785-96. 601 31. Anderson J, Phan L, Cuesta R, Carlson BA, Pak M, Asano K, Bjork GR, Tamame M and 602 Hinnebusch AG. The essential Gcd10p-Gcd14p nuclear complex is required for 1- 603 methyladenosine modification and maturation of initiator methionyl-tRNA. *Genes Dev*.
- 604 1998;12:3650-62.
- 605 32. Masuda I, Yamaki Y, Detroja R, Tagore S, Moore H, Maharjan S, Nakano Y, Christian T, 606 Matsubara R, Lowe TM, Frenkel-Morgenstern M and Hou YM. tRNA methylation resolves 607 codon usage bias at the limit of cell viability. *Cell Rep*. 2022;41:111539.
- 608 33. Doenst T, Nguyen TD and Abel ED. Cardiac metabolism in heart failure: implications 609 beyond ATP production. *Circ Res*. 2013;113:709-24.
- 610 34. Vasquez-Trincado C, Garcia-Carvajal I, Pennanen C, Parra V, Hill JA, Rothermel BA and 611 Lavandero S. Mitochondrial dynamics, mitophagy and cardiovascular disease. *J Physiol*. 612 2016;594:509-25.
- 613 35. Song M, Mihara K, Chen Y, Scorrano L and Dorn GW, 2nd. Mitochondrial fission and 614 fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured 615 fibroblasts. *Cell Metab*. 2015;21:273-286.
- 616 36. Ritterhoff J and Tian R. Metabolic mechanisms in physiological and pathological cardiac 617 hypertrophy: new paradigms and challenges. *Nat Rev Cardiol*. 2023;20:812-829.

- 618 37. Rosca MG, Tandler B and Hoppel CL. Mitochondria in cardiac hypertrophy and heart 619 failure. *J Mol Cell Cardiol*. 2013;55:31-41.
- 620 38. Ducker GS and Rabinowitz JD. One-Carbon Metabolism in Health and Disease. *Cell*  621 *Metab*. 2017;25:27-42.
- 622 39. Lu SC and Mato JM. S-adenosylmethionine in liver health, injury, and cancer. *Physiol*  623 *Rev*. 2012;92:1515-42.
- 624 40. Agrimi G, Di Noia MA, Marobbio CM, Fiermonte G, Lasorsa FM and Palmieri F. 625 Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial 626 expression, reconstitution, functional characterization and tissue distribution. *Biochem J*. 627 2004;379:183-90.
- 628 41. Chu PY, Wu HJ, Wang SM, Chen PM, Tang FY and Chiang EI. MAT2A Localization and 629 Its Independently Prognostic Relevance in Breast Cancer Patients. *Int J Mol Sci*. 2021;22.
- 630 42. Konteatis Z, Travins J, Gross S, Marjon K, Barnett A, Mandley E, Nicolay B, Nagaraja R,
- 631 Chen Y, Sun Y, Liu Z, Yu J, Ye Z, Jiang F, Wei W, Fang C, Gao Y, Kalev P, Hyer ML, DeLaBarre
- 632 B, Jin L, Padyana AK, Dang L, Murtie J, Biller SA, Sui Z and Marks KM. Discovery of AG-270,
- 633 a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP
- 634 Deletion. *J Med Chem*. 2021;64:4430-4449.
- 635 43. Kishita Y, Pajak A, Bolar NA, Marobbio CM, Maffezzini C, Miniero DV, Monne M,
- 636 Kohda M, Stranneheim H, Murayama K, Naess K, Lesko N, Bruhn H, Mourier A, Wibom R,
- 637 Nennesmo I, Jespers A, Govaert P, Ohtake A, Van Laer L, Loeys BL, Freyer C, Palmieri F,
- 638 Wredenberg A, Okazaki Y and Wedell A. Intra-mitochondrial Methylation Deficiency Due to
- 639 Mutations in SLC25A26. *Am J Hum Genet*. 2015;97:761-8.
- 640 44. Schober FA, Tang JX, Sergeant K, Moedas MF, Zierz CM, Moore D, Smith C, Lewis D,
- 641 Guha N, Hopton S, Falkous G, Lam A, Pyle A, Poulton J, Gorman GS, Taylor RW, Freyer C and



- 644 45. Ji Y, Wang S, Cheng Y, Fang L, Zhao J, Gao L and Xu C. Identification and 645 characterization of novel compound variants in SLC25A26 associated with combined oxidative 646 phosphorylation deficiency 28. *Gene*. 2021;804:145891.
- 647 46. Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA and Schneider MD. Gene 648 recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-649 restricted, site-specific rearrangement in adult ventricular muscle in vivo. *J Clin Invest*. 650 1997;100:169-79.
- 651 47. Pan T. Modifications and functional genomics of human transfer RNA. *Cell Res*. 652 2018;28:395-404.
- 653 48. Suzuki T. The expanding world of tRNA modifications and their disease relevance. *Nat*  654 *Rev Mol Cell Biol*. 2021;22:375-392.
- 655 49. Chou HJ, Donnard E, Gustafsson HT, Garber M and Rando OJ. Transcriptome-wide 656 Analysis of Roles for tRNA Modifications in Translational Regulation. *Mol Cell*. 2017;68:978- 657 992 e4.
- 658 50. Guimaraes JC, Mittal N, Gnann A, Jedlinski D, Riba A, Buczak K, Schmidt A and 659 Zavolan M. A rare codon-based translational program of cell proliferation. *Genome Biol*. 660 2020;21:44.
- 661 51. Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D, Erlacher M, 662 Rossmanith W, Stern-Ginossar N and Schwartz S. The m1A landscape on cytosolic and 663 mitochondrial mRNA at single-base resolution. *Nature*. 2017;551:251-255.
- 664 52. Ozanick SG, Bujnicki JM, Sem DS and Anderson JT. Conserved amino acids in each 665 subunit of the heteroligomeric tRNA m1A58 Mtase from Saccharomyces cerevisiae contribute to

- 666 tRNA binding. *Nucleic Acids Res*. 2007;35:6808-19.
- 667 53. Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, Zhu X, Gu Y, Dominissini D, He L,
- 668 Tian Y, Yi C and Fan Z. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis 669 by regulating cholesterol metabolism. *Nat Commun*. 2021;12:6314.
- 
- 670 54. Liu F, Clark W, Luo G, Wang X, Fu Y, Wei J, Wang X, Hao Z, Dai Q, Zheng G, Ma H,
- 671 Han D, Evans M, Klungland A, Pan T and He C. ALKBH1-Mediated tRNA Demethylation
- 672 Regulates Translation. *Cell*. 2016;167:816-828 e16.
- 673 55. Zhang L, Duan HC, Paduch M, Hu J, Zhang C, Mu Y, Lin H, He C, Kossiakoff AA, Jia G
- 674 and Zhang L. The Molecular Basis of Human ALKBH3 Mediated RNA N(1) -methyladenosine
- 675 (m(1) A) Demethylation. *Angew Chem Int Ed Engl*. 2024;63:e202313900.
- 676 56. Sun Y, Dai H, Dai X, Yin J, Cui Y, Liu X, Gonzalez G, Yuan J, Tang F, Wang N, Perlegos
- 677 AE, Bonini NM, Yang XW, Gu W and Wang Y. m(1)A in CAG repeat RNA binds to TDP-43 and 678 induces neurodegeneration. *Nature*. 2023;623:580-587.
- 679 57. Monne M, Marobbio CMT, Agrimi G, Palmieri L and Palmieri F. Mitochondrial transport 680 and metabolism of the major methyl donor and versatile cofactor S-adenosylmethionine, and 681 related diseases: A review(dagger). *IUBMB Life*. 2022;74:573-591.
- 682 58. Guitton R, Nido GS and Tzoulis C. No evidence of extensive non-CpG methylation in 683 mtDNA. *Nucleic Acids Res*. 2022;50:9190-9194.
- 684 59. Shirakabe A, Fritzky L, Saito T, Zhai P, Miyamoto S, Gustafsson AB, Kitsis RN and 685 Sadoshima J. Evaluating mitochondrial autophagy in the mouse heart. *J Mol Cell Cardiol*. 686 2016;92:134-9.
- 687 60. Kleele T, Rey T, Winter J, Zaganelli S, Mahecic D, Perreten Lambert H, Ruberto FP, 688 Nemir M, Wai T, Pedrazzini T and Manley S. Distinct fission signatures predict mitochondrial 689 degradation or biogenesis. *Nature*. 2021;593:435-439.



- 691 enzymes. *Chem Rev*. 2014;114:4229-317.
- 692 62. Wang D, Liu M, Li X, Wang X and Shen Y. Expression, purification and oligomerization 693 of the S-adenosylmethionine transporter. *Protein Expr Purif*. 2020;173:105648.
- 694 63. Kotter S and Kruger M. Protein Quality Control at the Sarcomere: Titin Protection and
- 695 Turnover and Implications for Disease Development. *Front Physiol*. 2022;13:914296.
- 696 64. Hanson G and Coller J. Codon optimality, bias and usage in translation and mRNA decay.
- 697 *Nat Rev Mol Cell Biol*. 2018;19:20-30.
- 698 65. Koutmou KS, Radhakrishnan A and Green R. Synthesis at the Speed of Codons. *Trends*  699 *Biochem Sci*. 2015;40:717-718.
- 700 66. Sabi R and Tuller T. Modelling the efficiency of codon-tRNA interactions based on codon 701 usage bias. *DNA Res*. 2014;21:511-26.
- 702 67. Li P, Wang W, Zhou R, Ding Y and Li X. The m(5) C methyltransferase NSUN2 703 promotes codon-dependent oncogenic translation by stabilising tRNA in anaplastic thyroid 704 cancer. *Clin Transl Med*. 2023;13:e1466.
- 705 68. Dou X, Boyd-Kirkup JD, McDermott J, Zhang X, Li F, Rong B, Zhang R, Miao B, Chen
- 706 P, Cheng H, Xue J, Bennett D, Wong J, Lan F and Han JJ. The strand-biased mitochondrial DNA 707 methylome and its regulation by DNMT3A. *Genome Res*. 2019;29:1622-1634.
- 708 69. Saini SK, Mangalhara KC, Prakasam G and Bamezai RNK. DNA Methyltransferase1 709 (DNMT1) Isoform3 methylates mitochondrial genome and modulates its biology. *Sci Rep*. 710 2017;7:1525.
- 711 70. Kim TS, Kim HD, Park YJ, Kong E, Yang HW, Jung Y, Kim Y and Kim J. JNK 712 activation induced by ribotoxic stress is initiated from 80S monosomes but not polysomes. *BMB*  713 *Rep*. 2019;52:502-507.



# 715 **Figure 1. Feedforward SAM transport into mitochondria by SLC25A26 during cardiac**  716 **hypertrophy**

717 **A**, Schematic illustrating the SAM biosynthesis and mitochondrial transport pathways.

- 718 **B** and **C**, Cell-type-specific expression of *MAT2A* (**B**) and *SLC25A26* (**C**) from a single-cell
- 719 sequencing database (Human Protein Atlas; https://www.proteinatlas.org/).
- 720 **D**, Western blot analysis showing the tissue specificity of MAT2A and SLC25A26 in mice (*N* =
- 721 2). Troponin T2, cardiac type (cTnT) was used as a positive heart control. Glyceraldehyde-3-
- 722 phosphate dehydrogenase (GAPDH) was used as a loading controls. SKM, skeletal muscle.
- 723 **E**, Total and subcellular SAM contents in the heart, skeletal muscle and liver. *N* = 3. Cyto, 724 cytoplasm; Mito, mitochondria.
- 725 **F**, Immunoblots (left) and quantification data (right) showing the expressions of MAT2A, 726 MAT2B and SLC25A26 in transaortic constriction (TAC)-induced cardiac hypertrophy. *N* = 3.
- 727 **G**, Time-course effects of TAC on the SAM content in the heart measured by enzyme-linked 728 immunosorbent assay (ELISA).  $N = 4$ .
- <sup>729</sup>**H**, SAM contents in neonatal rat ventricular myocytes (NRVMs) treated with SAM (1μM) or 730 phenylephrine (PE; 50μM), in the presence or absence of an MAT2A inhibitor AG-270 (3μM). *<sup>N</sup>*  $731 = 3.$
- 732 **I**, Effect of TAC on subcellular SAM distribution in fractionated mouse hearts.  $N = 3$ .
- 733 **J**, Subcellular SLC25A26 localization in fractionated mouse (left; *N* =3) and human (right; *N* =2)
- 734 hearts with H3, VDAC1 and GAPDH as nuclear (Nuc), Mito and Cyto controls, respectively.
- 735 **K**, Immunoblots (left) and quantification data (right) showing the impact of TAC on subcellular 736 SLC25A26 localization.  $N = 3$ .

- 737 **L**, Representative immunofluorescence images (upper) and quantification data (lower) showing
- 738 the co-localization of the Flag-tagged SLC25A26 with mitochondria (COX1) in NRVMs treated
- 739 with SAM or PE, with or without AG-270. \*\*\**P* < 0.001; *N* = 12. Scale, 5μm.
- 740 Data are mean ± SEM. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 vs. sham or vehicle, (**F**, **I** and **K**,
- 741 unpaired Student's t test; **G**, **H**, **L**, one-way ANOVA with Tukey's multiple comparison test).







744 **Figure 2. SLC25A26 is required for normal heart function and its deficiency exacerbates**  745 **TAC-induced cardiac hypertrophy** 

746 **A**, Schematic illustrating the generation of *Slc25a26* cardiac-specific knockout (cKO) mouse 747 line. WT, wildtype.

- 748 **B**, Validation of *Slc25a26* cKO by genotyping (left upper) and expression assessments at protein 749 (left lower) and mRNA (right) levels.  $N = 5$ .
- 750 **C**, Effects of *Slc25a26* cKO on heart and lung weights twenty weeks after Tamoxifen 751 administration.  $N = 9$ .
- 752 **D**, Representative heart morphology images (left) and low-magnification H&E-stained images 753 (right) of *Slc25a26*-flox and *Slc25a26*-cKO hearts. Scale, 0.5mm.
- 754 **E** through **G**, Representative Echocardiography images (**E**), quantification analyzed left 755 ventricular end diastolic/systolic internal dimensions (LVID;d/LVID;s; **F**), and quantification 756 analyzed left ventricular ejection fraction (EF) and fraction shortening (FS) (**G**) of *Slc25a26*-flox 757 and *Slc25a26*-cKO hearts twenty weeks after Tamoxifen administration. *N* = 9.
- 758 **H**, Representative Masson trichrome staining images (left) and quantification data (right) 759 showing myocardial fibrosis in *Slc25a26*-flox and *Slc25a26*-cKO hearts twenty weeks after 760 Tamoxifen administration. Scale, 20μm; *N* = 3.
- 761 **I**, Effects of *Slc25a26* cKO on the expression of hypertrophic biomarkers natriuretic peptide A 762 (*Nppa*), natriuretic peptide B (*Nppb*), and myosin heavy chain 7 (*Myh7*) measured by qRT-PCR. 763  $N = 9$ .
- 764 **J**, Representative heart morphology images (left) and summarized heart weight/body weight 765 (BW) ratios (right) showing the impact of *Slc25a26* cKO on TAC-induced cardiac hypertrophy.
- 766  $N = 7{\sim}12$  as labeled on bars.
- 767 **K**, Impact of  $\text{Slc25a26 cKO}$  on the lung weight/BW ratio in sham and TAC mice.  $N = 7 \sim 12$ .
- 768 **L** through **N**, Representative Echocardiography images (**L**), quantification analyzed end-diastolic
- 769 left ventricular posterior wall thickness (LVPW;d) and LVID;d (**M**), and quantification analyzed

- 770 EF and FS (**N**) showing the impact of *Slc25a26* cKO on TAC-induced cardiac morphology and 771 function.  $N = 7{\sim}12$  as mentioned above.
- 772 **O**, Representative H&E-stained images of *Slc25a26*-flox and *Slc25a26*-cKO hearts with sham or
- 773 TAC surgeries. Scale, 20μm.
- 774 **P**, Representative Wheat germ agglutinin (WGA) staining images (left) and quantification data
- 775 (right) showing the cross-sectional cardiomyocyte area of *Slc25a26*-flox and *Slc25a26*-cKO
- 776 hearts with sham or TAC surgeries. Scale, 20μm. *N* = 5.
- 777 **Q**, Representative Masson trichrome staining images (left) and quantification data (right) 778 showing myocardial fibrosis of *Slc25a26*-flox and *Slc25a26*-cKO hearts with sham or TAC 779 surgeries. Scale, 20μm; *N* = 3.
- 780 **R**, Effects of *Slc25a26* cKO on TAC-induced expressions of *Nppa*, *Nppb*, and *Myh7*. *N* = 5.
- 781 Data are mean  $\pm$  SEM. n.s., not significant, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 vs. flox;  $^{#}P$  <
- 782 0.05,  $^{#}/P$  < 0.01,  $^{#}/P$  < 0.001 vs. sham, (**B**, **C**, **F**, **G**, **H** and **I**, unpaired Student's *t* test; **J**, **K**, **M**,
- 783 **N**, **P**, **Q** and **R**, two-way ANOVA with Tukey's multiple comparison test).

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.07.30.24311193;](https://doi.org/10.1101/2024.07.30.24311193) this version posted August 2, 2024. The copyright holder for this preprint





785

- 787 **A**, Injection schedule of reconstructed adeno-associated virus serotype 9 (AAV9) to overexpress
- 788 *Slc25a26* in the heart before TAC.
- 789 **B**, Validation of *Slc25a26* overexpression using qRT-PCR. *N* = 5.
- 790 **C**, Effects of *Slc25a26* overexpression on TAC-induced heart weight gain. *N* = 6~10 as labeled 791 on bars.
- 792 **D** through **F**, Representative Echocardiography images (**D**), quantification analyzed LVPW;d 793 and LVID;d (**E**), and quantification analyzed EF and FS (**F**) showing the impact of pre-TAC 794 *Slc25a26* overexpression on TAC-induced cardiac morphological and functional changes. *N* = 795 6~10 as labeled on the bars.
- 796 **G**, Representative WGA staining images (left) and quantification data (right) showing the impact 797 of *Slc25a26* overexpression on TAC-induced cell size enlargement. Scale, 20μm. *N* = 3.
- 798 **H**, Representative Masson trichrome staining images (left) and quantification data (right) 799 showing the impact of *Slc25a26* overexpression on TAC-induced myocardial fibrosis. Scale, 800  $20 \mu m$ .  $N = 4$ .
- 801 **I**, Impact of *Slc25a26* overexpression on TAC-induced expression of cardiac hypertrophy 802 biomarkers measured by qRT-PCR. *N* = 5.
- 803 **J**, AAV9 injection schedules to overexpression *Slc25a26* after TAC in two strategies: Post1/Po1 804 (1w post-TAC) and Post2/Po2 (7w post-TAC).
- 805 **K**, Validation of *Slc25a26* overexpression in two post-TAC strategies using qRT-PCR. *N* = 5.
- 806 **L**, Effects of *Slc25a26* overexpression at two post-TAC schedules on TAC-induced heart weight 807 gain.  $N = 5{\sim}9$  as indicated by dots.









- 849 puromycin-incorporated peptides enriched by immunoprecipitation.
- 850 **N**, Protein counts detected by immunoprecipitation-mass-spectrum using anti-Puromycin
- 851 antibody in PE-treated NRVMs with *Slc25a26* knockdown or overexpression.
- 852 **O**, Plot of puromycin-incorporated proteins from PE-treated NRVMs with *Slc25a26* knockdown

853 or overexpression.

- 854 **P** and **Q**, Heatmap (left) and gene ontology (GO; right) analyses showing the functional clusters
- 855 of altered proteins by *Slc25a26* knockdown (**P**) or overexpression (**Q**).
- 856 **R**, Plot of the changes of translating proteins affected by *Slc25a26* knockdown in comparison
- 857 with their corresponding mRNA alterations from the RNA-seq analysis.
- 858 Data are mean  $\pm$  SEM. n.s., not significant, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 vs. flox or si*Neg*,

860

<sup>859 (</sup>**E**, **F**, **G** and **I**, unpaired Student's t test).



862



864 **A**, Frequency of  $m^1A$  modification in aligned tRNAs at single-nucleotide resolution.

865 **B**, Schematic illustrating the typical m<sup>1</sup>A-modified adenosines in the tRNA<sup>iMet</sup>, tRNA<sup>Gln</sup> and 866  $tRNA^{Thr}$ .

867 **C**, Schematic illustrating the m<sup>1</sup>A modification patterns in thetRNA<sup>Glu</sup> and tRNA<sup>Gly</sup>.





# 886 **Figure 6. SLC25A26/mitoSAM maintains mitochondrial fitness for optimal energy**  887 **production**

- 888 **A**, SAM contents in isolated mitochondria from the hearts with *Slc25a26* cKO (left) or 889 overexpression (right) measured by ELISA.  $N = 3$ .
- 890 **B**, Impact of *Slc25a26* overexpression on the methylation of mitochondrial 891 deoxyribonucleotides, including 5-methyl-2'-deoxycytidine (5-mdC), 5-(hydroxymethyl)-2'- 892 deoxycytidine (5-hmdC) and N6-methyl-2'-deoxyadenosine (6-mdA), measured by liquid 893 chromatography-mass spectrometry (LC-MS).  $N = 3$ .
- 894 **C**, ELISA measurement for mtDNA 5-mdC from the hearts with *Slc25a26* cKO (left) or 895 *Slc25a26* overexpression (right).  $N = 3$ .
- 896 **D**, mtDNA copy number calculated by the expressions of mitochondrial *Cytb* and *Nd1* in 897 contrast to the nuclear  $H19$  using qRT-PCR.  $N = 3$ .
- 898 **E** and **F**, Transmission electronic microscopy showing mitochondrial morphology (left) and 899 quantified abnormal mitochondria percentage (right) in the hearts with *Slc25a26* cKO (sham; **E**) 900 or  $Slc25a26$  overexpression (post-TAC; **F**).  $N = 3$ .
- 901 **G**, Immunoblots (left) and quantification data (right) of proteins involved in mitochondrial 902 dynamics in flox and cKO hearts.  $N = 3$ .
- 903 **H** and **I**, Representative fluorescence images (left) and quantification (right) of MitoKeima and 904 Lysotracker showing mitophagy in NRVMs with *Slc25a26* knockdown (**H**) or *Slc25a26* 905 overexpression (**I**). Scale, 10μm; *N* = 3.

